ArticleOncology letters2025
Real-world investigation for camrelizumab combined with apatinib in patients with advanced hepatocellular carcinoma.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of PD-1/PD-L1 inhibitors combined with anti-VEGF/TKIs and TACE in uHCC: a meta-analysis.Frontiers in oncology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apatinib, an oral tyrosine kinase inhibitor, combined with camrelizumab, a programmed cell death protein 1 inhibitor, has shown promising treatment efficacy for patients with advanced hepatocellular carcinoma (HCC). However, real-world evidence supporting this combination regimen is limited, and prognostic factors for these patients have not been thoroughly investigated. Therefore, the present real-world study aimed to assess the efficacy and safety of camrelizumab plus apatinib in patients with advanced HCC, and identify prognostic factors associated with response to treatment. A total of 39 patients with advanced HCC who received camrelizumab combined with apatinib were included in the present retrospective study. All patient data, such as treatment response, follow-up outcomes and incidence of adverse events were collected for analysis. The results revealed complete response, partial response, stable disease and progressive disease rates of 25.6, 10.3, 46.2 and 17.9%, respectively. In addition, the objective response and disease control rates were 35.9 and 82.1%, respectively. The median progression-free survival (PFS) was 24.0 months (95% confidence interval, 5.0-43.0). Furthermore, the cumulative PFS rates at 12, 24 and 36 months were 52.8, 44.0 and 39.1%, respectively. However, median overall survival (OS) was not reached during the follow-up period. The OS rates at 12, 24 and 36 months were 72.4, 72.4 and 66.3%, respectively. Multivariate Cox regression analysis also revealed that extrahepatic metastasis was independently associated with higher mortality risk (hazard ratio, 9.217; P=0.049). The most common adverse events were anemia (79.5%), thrombocytopenia (69.2%), leukopenia (64.1%), pain (56.4%), neutropenia (41.0%), fever (33.3%) and hypertension (28.2%). In conclusion, camrelizumab combined with apatinib shows promising treatment efficacy and a manageable toxicity in patients with advanced HCC. Additionally, extrahepatic metastasis could be associated with worse OS in these patients. Nevertheless, due to the small sample size, retrospective and single-arm study design in the current study, further study with a larger sample size, prospective, controlled design is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.